DBH and post-traumatic stress disorder: Since no DBH inhibitor has received marketing approval due to poor DBH selectivity, low potency, and/or significant side effects, DBH gene silencing with small interference RNA technology may be a potential new therapeutic alternative for PTSD, particularly in patients with increased sympathetic activity.